To date, several clinical trials have proposed that antiangiogenics combined with immunotheraputic strategies can achieve greater therapeutic efficacy compared with traditional tyrosine kinase inhibitors targeting VEGF or mTOR inhibitors alone, which has become an alternative first-line treatment for ccRCC in the clinic, emphasizing the crucial status of the tumor microenvironment (TME) (13, 14). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.